

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims (canceled): 1 through 49.

Claim 50 (new): A solid, oral, controlled release dosage form consisting of a therapeutically effective amount of oxycodone or oxycodone hydrochloride between about 30 and 65% by weight of a matrix-forming polymer selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose and hydroxyethyl cellulose and between about 1 and 20% by weight of a cationic exchange resin having a mean particle size of less than about 50  $\mu\text{m}$  and a particle size distribution such that not less than 90% of the particles pass through a 325 mesh sieve, U.S. Standard Sieve Size, wherein the oxycodone or oxycodone hydrochloride, the polymer and the cationic exchange resin are admixed with one another in dry form and then compressed.

Claim 51 (new): The dosage form of claim 50 wherein the cationic exchange resin comprises a sulfonated polymer.

Claim 52 (new): The dosage form of claim 50 wherein the cationic exchange resin comprises a copolymer of divinyl-benzene and styrene.

Claim 53 (new): The dosage form of claim 50 wherein the cationic exchange resin comprises a copolymer of divinylbenzene and methacrylic acid.

Claim 54 (new): The dosage form of claim 50 wherein the cationic exchange resin comprises phenolic-based polyamine condensates.